Anti-stromal nanotherapeutics for hepatocellular carcinoma
Journal of Controlled Release · 2024-03 · 367 · 500-514
DOI: 10.1016/j.jconrel.2024.01.050 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Controlled Release, 2024-03. Verfasst von Zhuo Yu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatopathy, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 188 Literaturangaben. Gefördert von: Department of Science and Technology of Jilin Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC), the most commonly diagnosed primary liver cancer, has become a leading cause of cancer-related death worldwide. Accumulating evidence confirms that the stromal constituents within the tumor microenvironment (TME) exacerbate HCC malignancy and set the barriers to current anti-HCC treatments. Recent developments of nano drug delivery system (NDDS) have facilitated the application of stroma-targeting therapeutics, disrupting the stromal TME in HCC. This review discusses the stromal activities in HCC development and therapy resistance. In addition, it addresses the delivery challenges of NDDS for stroma-targeting therapeutics (termed anti-stromal nanotherapeutics in this review), and provides recent advances in anti-stromal nanotherapeutics for safe, effective, and specific HCC therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hepatopathy, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
- Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA.
- School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China. Electronic address: jguo@jlu.edu.cn.
Förderung
- Department of Science and Technology of Jilin Province
- National Natural Science Foundation of China
Zitieren
APA
Yu, Z., Huang, L., & Guo, J. (2024). Anti-stromal nanotherapeutics for hepatocellular carcinoma. Journal of Controlled Release, 367, 500-514. https://doi.org/10.1016/j.jconrel.2024.01.050
Vancouver
Yu Z, Huang L, Guo J. Anti-stromal nanotherapeutics for hepatocellular carcinoma. Journal of Controlled Release. 2024;367:500-514. doi:10.1016/j.jconrel.2024.01.050
BibTeX
@article{Yu2024,
author = {Yu, Zhuo and Huang, Leaf and Guo, Jianfeng},
title = {Anti-stromal nanotherapeutics for hepatocellular carcinoma},
journal = {Journal of Controlled Release},
year = {2024},
volume = {367},
pages = {500--514},
doi = {10.1016/j.jconrel.2024.01.050}
}
EUVIMED